Source: IPSOS Health Survey 2025 #HealthcareInnovation #DigitalHealth #PharmaTrends #HealthCommunication #GLP1 #HealthTech #PatientEngagement #DataDrivenInsights #LifeSciences #HealthMarketing #GlobalHealth #FutureOfHealthcare The GLP-1 market is hot and will get hotter
In the SUSTAIN 8 trial, once-weekly add-on subcutaneous semaglutide was compared with add-on canagliflozin [18]
Chronic Management: Treating Obesity as a Chronic Disease Obesity is a risk factor for many other chronic conditions, including type 2 diabetes, kidney disease, heart disease, and non-alcoholic fatty liver disease
100% online
For many, the very first sign isnt a tan but a noticeable darkening of existing freckles or moles
FDA-approved GLP-1 pill and pens available Medication as low as $149/momembership fee of $39 for first month, $149 thereafter 100% online Choose the FDA-approved GLP-1 pill or injection and get a personalized weight loss plan built around you, if prescribed